XLO
Xilio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.00
−0.22%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
3.4x
Market Cap
$59.22M
MomentumView details →
1D Return
−0.22%
YTD Return
+1.90%
RSI (14)
52.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
3.4x
Market Cap
$59.22M
RSI (14)
52.8
MomentumView details →
1D Return
−0.22%
YTD Return
+1.90%
SummaryUpdated Jun 1, 2026
Xilio Therapeutics, Inc. (NASDAQ:XLO) is a clinical-stage biotechnology company founded in 2016 and headquartered in Waltham, Massachusetts. The company went public in October 2021 and focuses on developing innovative immunotherapies designed to enhance the immune system's ability to fight cancer. Xilio specializes in creating tumor-selective treatments that aim to overcome the limitations of traditional cancer immunotherapies by concentrating therapeutic activity specifically within the tumor microenvironment while minimizing systemic side effects.
Similar companies
Latest newsMore news →
Xilio Therapeutics received FDA clearance of its IND application for XTX501, a bispecific PD-1/masked IL-2 candidate.23d agoXilio Therapeutics reported Q2 2026 collaboration and license revenue of $18.7 million, up from $8.1 million in Q2 2025, with a net loss of $6.4 million compared to a $15.8 million loss a year earlier.24d ago